After the
Fall.

One of pharma's largest de-ratings in fifteen years.

The 67% drawdown from June 2024's peak is not narrative — it is justified by data. ROIC collapsed from 88.5% (FY23) to 39.3% (FY25). FY26 adjusted sales guidance was set at −4% to −12% CER. CagriSema failed its head-to-head trial vs Zepbound. The Wegovy WAC list price is cut 50% effective January 2027. Net debt grew DKK 116bn in 12 months.

Yet the franchise still operates at 45-49% EBITDA margins, and 45.6 million patients use Novo products globally. Wegovy pill — launched January 2026 — is running at 2× consensus. The question is whether these multi-year multiple lows are the bottom of the de-rate, or the trap door.

Three methods. Three scenarios. No overlay.

Our independent valuation uses three methods and three scenarios per method. Probabilities and weights are explicit; the formula determines the recommendation, not the reverse.

Each method runs Bull (20%) / Base (55%) / Bear (25%) scenarios. The Bear case carries a higher than typical weight because management credibility is damaged and the January 2027 WAC cut is unprecedented in scale.

How a 10% growth machine becomes −8%.

FY26 adjusted sales guidance of −4% to −12% CER translates to a midpoint of approximately DKK 284bn — down from DKK 309bn in FY25. The bridge reconstructs as thirteen drivers, half negative, half positive. Pricing is the structural overhang. Wegovy pill is the swing factor.

Pricing drag (rows 1+2+12) totals −DKK 42bn, the bear column. Wegovy pill (+DKK 9.5bn) is the standout green — Q1 2026 ran at DKK 2.26bn = ~DKK 9bn annualised, validating the bridge. Without Wegovy pill, FY26 sales would decline ~−11%, the bottom of management's range. With it, the midpoint becomes defensible.

Lilly is the structural threat — and the discount benchmark.

Novo's competitive position has bifurcated. In diabetes it remains the global leader. In obesity — the growth narrative — it has gone from monopoly (2021-22) to second-place oligopoly with Lilly becoming the strong #1.

The 41% discount on EV/EBITDA is striking. But the smaller 19% discount on forward P/E suggests the market is pricing in lower forward earnings, not just lower multiples. Crucially, Sanofi trades cheaper than NVO on forward P/E (8.9× vs 13.4×) — NVO is not even the cheapest pharma. The right benchmark is Roche or Novartis: defensive large-cap pharma. At those multiples, NVO is fairly valued, not a bargain.

Real value, but back-loaded.

Novo's pipeline contains 24+ active programmes weighted heavily toward obesity. Risk-adjusted peak sales (POA × Peak Sales) total approximately DKK 75-85bn — but 75% sits in Phase 3 with major catalysts in 2026-2028. There is no obvious "next semaglutide" before 2030.

CagriSema, in amber, is the most-watched single asset. The October 2026 FDA decision will determine whether Novo's combination obesity bet pays anything at all. Even approval will not restore the structural growth case lost in REDEFINE 4 — but it preserves optionality. Akero EFX's Q4 2026 Phase 3 readout is the most underappreciated catalyst — it validates the $5.2bn acquisition and opens the MASH franchise.

Five high-priority risks — most are already realised.

Neither a bargain nor a trap. Fair value.

Novo Nordisk at $44.96 is correctly priced. The math derives a $45.90 target — essentially a tie with the current price. The 4% dividend yield brings total expected return to roughly 6%. This is neither a value trap nor a bargain; it is a stock that has correctly priced in real deterioration.

Why not BUY at $45?

Two reasons. First, the math says ~2% upside before dividends — below the threshold for a BUY rating. Second, the bear case ($25.34 composite) represents a real, quantifiable risk path. A scenario-weighted approach that honestly assigns 25% probability to severe downside cannot logically generate a BUY recommendation when the central case is roughly flat. Buying NVO here is a bet that the worst is behind, not a margin-of-safety trade.

Why not SELL?

Three reasons. The 4% dividend yield with solid coverage pays you to wait. NVO trades below intrinsic fair value in the Base case across all three methods — there is no margin of safety for shorts. And Wegovy pill outperformance in Q1 2026 demonstrated franchise resilience; the story is not over.

What would change the rating

To BUY: Wegovy pill sustained at 250k+/wk plus CagriSema clean approval plus EFX Ph3 positive equals multiple expansion to ~13× EV/EBITDA — target jumps to $55-60. To AVOID: Wegovy pill plateau below 150k/wk plus CagriSema rejection plus M&A spree exceeds $25bn — Bear case validates, target falls to $25-30.